Bezlotoxumab, an IgG1 monoclonal antibody targeting C. difficile toxin B, is recommended for high-risk patients to prevent further recurrences. While the addition of bezlotoxumab has shown benefit ...

People with recurrent infections are at higher risk of complications. The C. diff bacteria can produce toxins that irritate ...

However, because antibiotics also target beneficial bacteria in the gut microbiome, C. difficile often takes advantage of their absence, releasing toxins in the colon that allow C. difficile to ...

Hypoxia-inducible factor (HIF) signaling protects the intestinal mucosa from injury induced by Clostridium difficile toxins, according to the results of a study published in Gastroenterology.

Clostridioides difficile infection is a major healthcare-associated infection, causing significant morbidity and mortality, ...

difficile treatment. Oral FZ002 is a live yeast genetically modified to express a tetraspecific anti-toxin for C. difficile in the gastrointestinal (GI) tract. FZ002 is a first-in-class multi ...

This strategy allows efficient signal amplification, thus yielding potent diarrheagenic or emetic toxins. STa was the first ligand found to bind GC–C, and later studies demonstrated that the ...

The C-terminal part of A2 extends through the central pore of the B pentamer, and is linked noncovalently to the B-subunits. Intracellularly active toxins can target molecules that have a pivotal ...